If you're having problems viewing this message, please click here for additional help.

June, 2008                                                                                                                            Home

1. Well Characterized Biospecimens for biomarker discovery and validation Biomarker Development has been identified as one of the most important areas for improving drug development and diagnosis by The FDA’s Critical Path Initiative. Critical Path is the FDA's premier initiative to identify and prioritize the most pressing medical product development problems and the greatest opportunities for rapid improvement in public health benefits. Under this initiative, the FDA has created an Opportunities List which outlines an initial 76 projects to bridge the gap between the quick pace of new biomedical discoveries and the slower pace at which those discoveries are currently developed into therapies. The Critical Path Opportunities Report is organized into six broad topic areas: development of biomarkers; clinical trial designs, bioinformatics, manufacturing, public health needs and pediatrics.    (full story) 2. Biomarker validation services To complement our world-leading human tissue procurement network, Asterand offers biomarker validation services under its PhaseZERO® Drug Discovery Services platform.   (full story) 3. Human tissue based models for extrahepatic metabolism research Asterand's PhaseZERO® research services provide pharmaceutical companies with human tissue-based data to help select / support the progression of drug candidates with the goal of increasing the likelihood of clinical success. To expand our human ADMET services, we have recently developed a model to study metabolism in human lung (mixed parenchymal cells)1. We have also recently demonstrated phase I and phase II metabolism in gut (fresh, whole mucosa) and skin (keratinocytes)2. Work is ongoing to characterize the drug metabolism in human bronchial epithelial cells and human isolated enterocytes.   (full story) Technology Spotlight Human tissue based pharmacology models for urology research Product Focus Now Available Late stage Carcinoma Associated Fibroblasts from prostate, lung and breast cancers Available separately or tumor and adjacent normal pair Purchase Online Meet us at: 9th Annual Drug Discovery Leaders Summit June 16-18, Switzerland European Pharmacology meeting (EPHAR 2008) July 13-17, Manchester, UK Visit us at www.Asterand.com                  Asterand - A Global Provider of Human Tissues and Services

Asterand, Inc. (US Laboratory) , TechOne Suite 501 , 440 Burroughs , Detroit, MI 48202-3420 U.S.A. , 313.263.0960 Asterand UK Limited (UK Laboratory) , 2 Orchard Road , Royston,Hertfordshire, SG8 5HD, UK , +44 (0)1763 211600 To unsubscribe click here